Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their ...

Overview: Novo Remains a Leader in Diabetes and Weight Loss My continued opinion of Novo as an investment ... In the most ...

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk’s weight-loss and diabetes drugs but cannot ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...